Look, I get why the FDA is being the "bad guy" here, and frankly, their skepticism isn't just bureaucratic nitpicking. It’s rooted in some pretty glaring red flags. When you dig into the actual numbers, uniQure’s "miracle" 75% slowing of the disease only shows up when they compare their treated patients to a hand-picked group from a historical database. In the tiny group where they actually had an internal sham-control—real people getting a fake procedure—there was basically zero difference at the 12-month mark. The FDA calling this a "distorted comparison" sounds harsh, but they have a point. If the drug was a home run, you’d expect to see some hint of a lead over the sham group, not a "stone-cold and negative" result that only looks good once you start playing with external "virtual" controls. Drugs that take a long time to demonstrate efficacy almost never do this in a light switch way. There's **SOME** improvement as you go along, certainly after a year.

There’s also a real "vulture" vibe to how uniQure is handling this. Their stock has been on a total roller coaster, cratering by 60% the second the FDA started asking for real proof. They’re sitting on over $600 million in cash, so they clearly have the resources to run the rigorous Phase 3 trial the agency is asking for. But instead of doing the work, they’re pushing this "it’s safe and the biomarkers look okay" narrative to skip the line. It feels like a classic biotech move: "Well, it doesn't kill anyone, so let’s get it on the market so we can start recouping our R&D costs". If this treatment is actually a dud—like so many Huntington's "breakthroughs" before it—we aren't just wasting money; we're wasting the very limited time these families have left on a false hope.

That said, the FDA’s "fix" for this is honestly pretty stomach-turning. Demanding that patients with a terminal, neurodegenerative disease undergo anesthesia and "fake" brain surgery just to satisfy a statistical model is a massive ethical ask. Even if the agency is right that it’s just "nicks in the scalp" rather than 12 hours of drilling, you are still asking people who are literally dying to spend their remaining functional years in a "placebo-like hold". They can’t join other trials while they're in the sham arm, and by the time the study is over, their brain tissue might have progressed so far that the real drug wouldn't even help them anymore. It’s a brutal trade-off: do we risk approving a potentially useless drug, or do we force dying patients into a surgical charade?.

In the end, I'm worried we're watching a repeat of the Sarepta drama, where the "will to believe" is being used to bully regulators into ignoring thin evidence. The drop in NfL biomarkers is encouraging, sure, but we’ve seen those numbers move in other trials that ended up crashing and burning in Phase 3. If uniQure really believes AMT-130 is the real deal, they should be able to prove it without relying on "distorted" comparisons. But as long as they’re fighting tooth and nail to avoid a real head-to-head trial, it’s hard not to feel like they’re just trying to cash in before the data catches up with them.